新型调节剂联合治疗在囊性纤维化患者中的真实世界临床结局(RECOVER)

RECOVER 是一项基于 clinicaltrials.gov 的真实世界研究数据集,聚焦囊性纤维化(CF)患者接受 ETI 新型调节剂联合治疗后的临床结局

Royal College of Surgeons, IrelandRoyal College of Surgeons, Ireland
clinicaltrials
浏览 9
医学影像预测Cystic FibrosisCystic Fibrosis Liver DiseaseCystic Fibrosis in ChildrenAdherence, MedicationCystic Fibrosis Gastrointestinal Disease
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)

基本信息

模态
医学影像
任务类型
预测
创建/更新时间
2026-10-12

资源简介

新型调节剂联合治疗在囊性纤维化患者中的真实世界临床结局(RECOVER)

RECOVER 是一项基于 clinicaltrials.gov 的真实世界研究数据集,聚焦囊性纤维化(CF)患者接受 ETI 新型调节剂联合治疗后的临床结局。覆盖人群包括儿童 CF、CF 肝病与 CF 胃肠道疾病患者,并关注用药依从性。研究除采用肺功能、营养、急性加重和肝病等传统监测指标外,还纳入肺清除指数(LCI)和肺功能控制胸部 CT 等非常规结局指标,并配套全面的生物样本采集方案,可用于评估治疗对多领域健康结局的影响(来源 clinicaltrials.gov)。

【数据内容】

源站描述(机器翻译,仅供参考):条件:囊性纤维化、囊性纤维化肝病、儿童囊性纤维化、依从性、用药、囊性纤维化胃肠道疾病。RECOVER 的目标是在真实世界环境中考察 ETI 对囊性纤维化患者关键临床结局的临床影响。在本研究中,除了监测囊性纤维化患者临床结局的一些较传统方式(如标准肺功能、营养、急性加重和肝病)之外,研究者还提议纳入一些临床试验中通常不使用的全新结局指标,例如肺清除指数(LCI)和肺功能控制胸部 CT。通过实施一项广泛的研究方案,纳入囊性纤维化患者多个健康领域的重要结局,并将其与全面的生物样本采集计划相匹配,研究者将有能力获得重要

【主题与分类】

主题标签:Cystic Fibrosis、Cystic Fibrosis Liver Disease、Cystic Fibrosis in Children、Adherence, Medication、Cystic Fibrosis Gastrointestinal Disease。本站分类:呼吸系统疾病。

【获取与许可】

源站页面:https://clinicaltrials.gov/study/NCT04602468

官方服务

专家保障全链路合规授权与标注交付

陕川双基地 × 超十家三甲医院直连

从合规授权、采集治理、专业标注到数据集交付,我们提供全链路闭环服务,让高质量临床数据即拿即用。

⚡️ 需要原始数据或标注支持?联系我们获取定制方案。

帮我联系

下载信息

注册下载

需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。

暂未开放

公开下载

无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。

免登录

当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。

免费样本无法满足模型训练要求?千方提供经三甲医院脱敏、带病理回证与专家标注的商业级专病数据集。

使用方式

数据集获取

源站:https://clinicaltrials.gov/study/NCT04602468

标准获取流程:

  1. 访问源站链接,注册/登录账号;
  2. 进入数据集详情页,按页面指引申请权限或直接下载;
  3. 部分平台提供 SDK,例如:
    • OpenDataLab: pip install openxlab 后 openxlab.dataset.get(...)
    • ModelScope: pip install modelscope 后 modelscope download
    • 天池: 登录后页面提供直链下载
      以源站「数据下载/使用文档」页面为准。

数据说明

Conditions: Cystic Fibrosis, Cystic Fibrosis Liver Disease, Cystic Fibrosis in Children, Adherence, Medication, Cystic Fibrosis Gastrointestinal Disease. Our aim with RECOVER is to examine the clinical impact of ETI on key clinical outcomes in people with CF in a real-world setting. For this study, in addition to some of the more traditional ways of monitoring clinical outcomes in people with CF such a standard lung function, nutrition, exacerbations and liver disease, the investigators are proposing to include some novel outcome measures not typically used in clinical trials such as lung clearance index (LCI) and spirometry controlled chest CT. By implementing an extensive study protocol that will include important outcomes in a number of areas of health in people with CF, and matching this to a comprehensive biosample collection plan, the investigators will have the power to gain important insight into how ETI works, and what impact it has on rescue of CFTR function in this group of people. Data on the following outcomes will be collected during the study: Lung Clearance Index Ultra-low dose, spirometry-controlled CT scanning Sweat Chloride Nasal Lavage (inflammatory markers and microbiome) Fraction of Exhaled Nitric Oxide (FeNO) Liver Ultrasound Liver examination (signs of liver disease) Sputum Collection (inflammatory markers and microbiome) Stool Collection (inflammation, microbiome, fecal elastase) Abdominal symptom questionnaire CFQ-R (quality of life) Adherence to treatment Height, weight, BMI Forced Expiratory volume in 1 second (FEV1) Microbiological culture of airway specimens (clinical laboratories at sites) Mental Health outcomes The Lead Investigator is Paul McNally, with Prof. Jane Davies as Co-Lead Investigator. The study will operate in collaboration with our academic and clinical partners and the CF registries in Ireland and the UK. The study is supported by the European CF Society Clinical Trials Network (ECFS-CTN). The study is being run as a CTIMP in the UK clinical sites, as determined by the MHRA. In the Irish sites, the HPRA has determined this study to be an observational research study.

数据加载示例(图像类)

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

需要用于商业化训练或医疗器械注册(NMPA/FDA)?

公开数据往往缺乏完整的病理回证与专家标注。千方医数集依托陕川双基地与超十家三甲医院直连,提供完全合规、去标识化、支持注册级质控的专病数据集交易服务。